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outcome from pituitary surgery of macroadenoma including failure to relieve symptoms, neurological deficit, and death; outcome from pituitary surgery of microadenoma including failure to relieve symptoms (of hyperprolactinemia, Cushing's syndrome, and acromegaly), neurological deficit, and death; quality of life values for various health states including hyperprolactinemia, Cushing's syndrome, acromegaly, bromocriptine treatment, incidental microadenoma (after 2 years), incidental microadenoma (first 2 years), and stroke or neurological deficit; and relative risk of death for acromegaly, and Cushing's syndrome.
The test characteristics (sensitivity, specificity, accuracy) and effectiveness of bromocriptine were discussed.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
A total of 16 papers were directly referred to as sources of clinical probabilities incorporated in the model. An extra set of 16 papers was referred to in the discussion on the test characteristics and effectiveness of bromocriptine.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The outcome results (range for sensitivity analyses) were as follows:
probability of a positive test with MRI (annual incidental microadenoma growth rate), 0.017 (0.0017-0.17); quality of life values for various health states including hyperprolactinemia, 1.00 (0.9-1.00), Cushing's syndrome, 1.00 (0.9-1.00), acromegaly, 1.00 (0.9-1.00), bromocriptine treatment, 1.00 (0.9-1.00), incidental microadenoma (after 2 years), 1.00, incidental microadenoma (first 2 years), 0.99 (0.90-0.99), and stroke or neurological deficit, 0.75 (0.74-0.77); relative risk of death for acromegaly, 2.01 (1.00-2.01), and Cushing's syndrome, 3.84 (1.00-3.84).
It was reported that the data on test characteristics (sensitivity, specificity, accuracy) and effectiveness of bromocriptine for patients with incidental asymptomatic pituitary microadenoma were not readily available. Further details on probabilities are provided in the paper.
Methods used to derive estimates of effectiveness
Clinical judgement (consensus of four physicians, of whom two were endocrinologists) was also used to derive estimates of effectiveness.
Estimates of effectiveness and key assumptions
The outcome results were as follows: quality of life value for the health state of no endocrinopathies or neurological deficits, 1.00; relative risk of death for hyperprolactinemia, 1.02 (1.00-1.02), and for bromocriptine, 1.01 (1.00-1.01).
Measure of benefits used in the economic analysis
The benefit measure was quality-adjusted life years (QALYs) for a time horizon of 10 years (range for sensitivity analyses, 2-50 years).
